NO20045535L - Fremgangsmate for a fremme roykeavvenning - Google Patents
Fremgangsmate for a fremme roykeavvenningInfo
- Publication number
- NO20045535L NO20045535L NO20045535A NO20045535A NO20045535L NO 20045535 L NO20045535 L NO 20045535L NO 20045535 A NO20045535 A NO 20045535A NO 20045535 A NO20045535 A NO 20045535A NO 20045535 L NO20045535 L NO 20045535L
- Authority
- NO
- Norway
- Prior art keywords
- smoking cessation
- procedure
- promoting smoking
- promoting
- reboxetine
- Prior art date
Links
- 230000005586 smoking cessation Effects 0.000 title abstract 6
- 230000001737 promoting effect Effects 0.000 title abstract 2
- 239000003623 enhancer Substances 0.000 abstract 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 2
- 229960002715 nicotine Drugs 0.000 abstract 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 2
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 abstract 2
- 229960003770 reboxetine Drugs 0.000 abstract 2
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 239000003401 opiate antagonist Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39289302P | 2002-07-01 | 2002-07-01 | |
| PCT/US2003/016232 WO2004002463A2 (en) | 2002-07-01 | 2003-06-26 | Method of promoting smoking cessation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20045535L true NO20045535L (no) | 2005-01-27 |
Family
ID=30000949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20045535A NO20045535L (no) | 2002-07-01 | 2004-12-17 | Fremgangsmate for a fremme roykeavvenning |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20040102440A1 (de) |
| EP (1) | EP1534254A2 (de) |
| JP (1) | JP2005531631A (de) |
| CN (1) | CN1665511A (de) |
| AP (1) | AP2004003188A0 (de) |
| AU (1) | AU2003253609A1 (de) |
| BR (1) | BR0312293A (de) |
| CA (1) | CA2491549A1 (de) |
| EA (1) | EA200401584A1 (de) |
| EC (1) | ECSP045517A (de) |
| HR (1) | HRP20041194A2 (de) |
| IL (1) | IL165882A0 (de) |
| IS (1) | IS7600A (de) |
| MA (1) | MA27597A1 (de) |
| MX (1) | MXPA05000296A (de) |
| NO (1) | NO20045535L (de) |
| OA (1) | OA12878A (de) |
| PL (1) | PL373620A1 (de) |
| RS (1) | RS115204A (de) |
| TN (1) | TNSN04267A1 (de) |
| WO (1) | WO2004002463A2 (de) |
| ZA (1) | ZA200410339B (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| ES2285233T3 (es) | 2002-12-20 | 2007-11-16 | Niconovum Ab | Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable. |
| EP1617832B1 (de) | 2003-04-29 | 2008-03-12 | Orexigen Therapeutics, Inc. | Zusammensetzungen zur beeinflussung des gewichtsverlusts |
| EP1870096A3 (de) * | 2003-04-29 | 2011-04-20 | Orexigen Therapeutics, Inc. | Zusammensetzungen zur Beeinflussung von Gewichtsverlust |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| CN101534808A (zh) * | 2005-06-27 | 2009-09-16 | 拜维尔实验室国际有限公司 | 丁氨苯丙酮盐的改良释放配制品 |
| CN101370488B (zh) | 2005-11-22 | 2012-07-18 | 奥雷西根治疗公司 | 增加胰岛素敏感性的组合物 |
| US9402809B2 (en) | 2006-03-16 | 2016-08-02 | Niconovum Usa, Inc. | Snuff composition |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| US20070297991A1 (en) * | 2006-06-23 | 2007-12-27 | Minu, L.L.C. | Neural conduit agent dissemination for smoking cessation and other applications |
| KR20170077291A (ko) | 2006-11-09 | 2017-07-05 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
| EP2170274A1 (de) * | 2007-07-02 | 2010-04-07 | Technion Research and Development Foundation, Ltd. | Zusammensetzungen, artikel und verfahren mit tspo-liganden zur verhinderung oder verringerung von tabakbedingten schäden |
| WO2009158114A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| US20100069389A1 (en) * | 2008-09-06 | 2010-03-18 | Bionevia Pharmaceuticals, Inc. | Novel forms of reboxetine |
| US20110046116A1 (en) * | 2009-08-20 | 2011-02-24 | Cukrowski Walter J | Sedative for use during eye surgery |
| CN102573821A (zh) * | 2009-09-30 | 2012-07-11 | 哈兰·克莱顿·比利 | 保持体重的戒烟法及营养补充剂 |
| MX344303B (es) | 2010-01-11 | 2016-12-13 | Orexigen Therapeutics Inc | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. |
| SG10201505217WA (en) | 2010-07-09 | 2015-08-28 | Biogen Hemophilia Inc | Chimeric clotting factors |
| CN110893181A (zh) | 2012-06-06 | 2020-03-20 | 纳丙药业有限责任公司 | 治疗超重和肥胖症的方法 |
| WO2015054730A1 (en) * | 2013-10-14 | 2015-04-23 | Palmaya Pty Ltd | Compositions and methods of administering same |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| US9192570B2 (en) | 2013-12-20 | 2015-11-24 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| CN104381577A (zh) * | 2014-11-18 | 2015-03-04 | 安徽润康保健食品有限公司 | 一种具有戒烟功能的口香糖 |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| WO2020168337A1 (en) | 2019-02-17 | 2020-08-20 | Magid Abraham | Compositions and methods for treatment of depression and other disorders |
| CA3166250A1 (en) | 2020-02-05 | 2021-08-12 | Gregory G. Plucinski | Drug products for intranasal administration and uses thereof |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
| US12565478B1 (en) | 2025-01-21 | 2026-03-03 | Axsome Therapeutics, Inc. | (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL138855A0 (en) * | 1998-04-09 | 2001-10-31 | Upjohn Co | New treatments for nervous disorders |
| PT1075264E (pt) * | 1998-05-08 | 2005-01-31 | Upjohn Co | Novas combinacoes farmacologicas de reboxetina e pindolol |
| US6465458B1 (en) * | 1999-07-01 | 2002-10-15 | Pharmacia & Upjohn Company | Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor |
| DE10004547A1 (de) * | 2000-02-02 | 2001-08-09 | Liedtke Pharmed Gmbh | Verfahren zur selektiven Verabreichung zentralnervös aktiver Stoffe |
-
2003
- 2003-06-24 US US10/602,447 patent/US20040102440A1/en not_active Abandoned
- 2003-06-26 MX MXPA05000296A patent/MXPA05000296A/es not_active Application Discontinuation
- 2003-06-26 CN CN038156369A patent/CN1665511A/zh active Pending
- 2003-06-26 JP JP2004517572A patent/JP2005531631A/ja active Pending
- 2003-06-26 CA CA002491549A patent/CA2491549A1/en not_active Abandoned
- 2003-06-26 AU AU2003253609A patent/AU2003253609A1/en not_active Abandoned
- 2003-06-26 RS YUP-1152/04A patent/RS115204A/sr unknown
- 2003-06-26 BR BR0312293-0A patent/BR0312293A/pt not_active IP Right Cessation
- 2003-06-26 EA EA200401584A patent/EA200401584A1/ru unknown
- 2003-06-26 WO PCT/US2003/016232 patent/WO2004002463A2/en not_active Ceased
- 2003-06-26 OA OA1200400348A patent/OA12878A/en unknown
- 2003-06-26 AP AP200403187D patent/AP2004003188A0/xx unknown
- 2003-06-26 PL PL03373620A patent/PL373620A1/xx not_active Application Discontinuation
- 2003-06-26 HR HR20041194A patent/HRP20041194A2/xx not_active Application Discontinuation
- 2003-06-26 EP EP03761901A patent/EP1534254A2/de not_active Ceased
-
2004
- 2004-12-16 IS IS7600A patent/IS7600A/is unknown
- 2004-12-17 MA MA28018A patent/MA27597A1/fr unknown
- 2004-12-17 NO NO20045535A patent/NO20045535L/no not_active Application Discontinuation
- 2004-12-20 IL IL16588204A patent/IL165882A0/xx unknown
- 2004-12-22 ZA ZA200410339A patent/ZA200410339B/en unknown
- 2004-12-28 EC EC2004005517A patent/ECSP045517A/es unknown
- 2004-12-30 TN TNP2004000267A patent/TNSN04267A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| OA12878A (en) | 2006-09-15 |
| IL165882A0 (en) | 2006-01-15 |
| HRP20041194A2 (en) | 2005-06-30 |
| MXPA05000296A (es) | 2005-08-19 |
| CN1665511A (zh) | 2005-09-07 |
| PL373620A1 (en) | 2005-09-05 |
| CA2491549A1 (en) | 2004-01-08 |
| EA200401584A1 (ru) | 2005-08-25 |
| US20040102440A1 (en) | 2004-05-27 |
| WO2004002463A2 (en) | 2004-01-08 |
| IS7600A (is) | 2004-12-16 |
| ZA200410339B (en) | 2006-07-26 |
| EP1534254A2 (de) | 2005-06-01 |
| JP2005531631A (ja) | 2005-10-20 |
| ECSP045517A (es) | 2005-03-10 |
| RS115204A (sr) | 2007-02-05 |
| BR0312293A (pt) | 2005-04-12 |
| AP2004003188A0 (en) | 2004-12-31 |
| WO2004002463A3 (en) | 2004-02-19 |
| AU2003253609A1 (en) | 2004-01-19 |
| MA27597A1 (fr) | 2005-11-01 |
| TNSN04267A1 (fr) | 2007-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20045535L (no) | Fremgangsmate for a fremme roykeavvenning | |
| ATE479686T1 (de) | Pyridopyrrolizin- und pyridoindolizinderivate | |
| NO20081250L (no) | Kombinasjon av hypnotisk middel med langtidsvirkning og hypnotisk middel med korttidsvirkning, samt terapeutisk anvendelse av samme | |
| TNSN07195A1 (en) | Potentiators of glutamate receptors | |
| AU2002344951A1 (en) | Substituted piperazine and diazepanes as histamine h3 receptor agonists | |
| BR0313233A (pt) | Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, e, composição farmacêutica | |
| SG167664A1 (en) | 2,4-pyrimidinediamine compounds and their uses | |
| EE05287B1 (et) | Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon | |
| HUP0301122A2 (hu) | Gyógyszerkombinációk és gasztrointesztinális rendellenességek kezelésében való alkalmazásuk | |
| MXPA05010174A (es) | Derivados de indol e indolina sustituidos. | |
| CY1111477T1 (el) | Θειενοπυριδινες ως αλλοστερικοι ενισχυτες του μ4 μουσκαρινικου υποδοχεα | |
| DE602006007556D1 (de) | Heteroarylsulfonylstilbene als 5-ht2a-antagonisten | |
| GEP20104962B (en) | Fused heterocyclic compounds | |
| EA200300183A1 (ru) | Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции | |
| DE60329330D1 (de) | Piperidin- und pyrrolidin-derivate alsantagonisten des histamin-h3-rezeptors | |
| MY140886A (en) | Piperazinyl and diazapanyl benzamides and benzthioamides | |
| HUP9800938A2 (hu) | NK-1 receptor antagonisták alkalmazása irritációs bélszindróma tüneteinek kezelésére | |
| DK1581538T3 (da) | Tetracykliske 3-substituerede indoler med serotoninreceptoraffinitet | |
| CY1109694T1 (el) | Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης | |
| UA87122C2 (ru) | Агонисты рецепторов глюкагонподобного пептида-1, их применение и способ получения | |
| NZ552328A (en) | Arylsulphonylstilbene derivatives for treatment of insomnia and related conditions | |
| AR035600A1 (es) | Uso de agonistas selectivos del receptor de dopamina d4 en la fabricacion de medicamentos para tratar la disfuncion sexual | |
| ATE325115T1 (de) | Pyrimidinderivate als selektive cox-2-inhibitoren | |
| DK1420789T3 (da) | Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling | |
| EA200900575A1 (ru) | Композиция, содержащая антагонист рецептора nk1 и ssri, для лечения шума в ушах и потери слуха |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |